IBERIABANK Corporation Declares Cash Dividend
Get Alerts IBKC Hot Sheet
Join SI Premium – FREE
LAFAYETTE, La., March 17, 2015 /PRNewswire/ -- The Board of Directors of IBERIABANK Corporation (NASDAQ: IBKC) announced the declaration of a quarterly cash dividend of $0.34 per share. The dividend is payable on April 24, 2015, to shareholders of record as of March 31, 2015. This dividend level equates to an annualized dividend rate of $1.36 per share. Based on the closing stock price on March 16, 2015, of $63.85 per share, the Company had a market capitalization of approximately $2 billion and the indicated dividend yield was 2.13%.
The Company's common stock trades on the NASDAQ Global Select Market under the symbol "IBKC."
IBERIABANK Corporation shareholders may take advantage of the Company's Dividend Reinvestment Plan. This program provides a convenient, economical way for shareholders to increase their holdings of the Company's common stock. The shareholder pays no brokerage commissions or service charges while participating in the plan.
To enroll in IBERIABANK Corporation's Dividend Reinvestment Plan, shareholders must have their stock certificate numbers and complete an enrollment form. Enrollment forms and a summary of the plan are available from the Registrar and Transfer Company by calling (800) 368-5948.
IBERIABANK Corporation is a financial holding company based in Lafayette, Louisiana with locations in 10 states. IBERIABANK Corporation and its predecessor organizations have served clients for 128 years.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/iberiabank-corporation-declares-cash-dividend-300051739.html
SOURCE IBERIABANK Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ScitiX Introduces Production-Ready Inference Platform, Bringing Enterprise-Grade Control to Multi-Model AI Deployments
- Fishing history delivers Schmitt's third Bassmaster Elite title at Lake Champlain
- HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Can
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share